Squadron Capital Llc Sells 18,000 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 18,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00. Following the completion of the transaction, the insider directly owned 6,863,464 shares of the company’s stock, valued at approximately $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total value of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total value of $103,000.00.

OrthoPediatrics Stock Performance

KIDS opened at $23.32 on Friday. The company has a market capitalization of $608.89 million, a price-to-earnings ratio of -13.88 and a beta of 0.98. The business’s 50-day moving average price is $21.32 and its two-hundred day moving average price is $18.62. OrthoPediatrics Corp. has a 1 year low of $14.42 and a 1 year high of $26.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Equities analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

KIDS has been the subject of several research reports. Needham & Company LLC raised their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. BTIG Research boosted their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

Key Headlines Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of OrthoPediatrics in the second quarter valued at $24,347,000. Millennium Management LLC increased its holdings in OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after buying an additional 452,840 shares during the last quarter. AIGH Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter worth $5,161,000. Nantahala Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter worth $4,636,002,000. Finally, AWM Investment Company Inc. acquired a new stake in OrthoPediatrics in the second quarter valued at $4,537,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.